<p>Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股价在周三的午盘交易中上涨了 9%，原因是其财报超出预期。该股最高交易价为 21.46 美元，最后交易价为 21.6620 美元。午盘交易中成交了 878,698 股，较平均交易量 1,028,993 股下降了 15%。该股此前收盘价为 19.88 美元。</p>
<ul>
<li>从滞后者到领头羊：小型股正在崛起</li>
</ul>
<p>该公司报告本季度每股收益为（1.27 美元），超出分析师一致预期的（1.33 美元）0.06 美元。Arcus Biosciences 的股本回报率为负 55.96%，净利润率为负 109.56%。该季度的收入为 2600 万美元，而分析师预期为 1989 万美元。去年同期，该公司的每股收益为（1.00 美元）。Arcus Biosciences 本季度的收入同比下降了 45.8%。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对该公司进行了评论。Truist Financial 在 10 月 7 日的研究报告中重申了 “买入” 评级，并将 Arcus Biosciences 的目标价从 32.00 美元上调至 39.00 美元。华尔街 Zen 在 8 月 9 日的研究报告中将 Arcus Biosciences 的评级从 “强烈卖出” 上调至 “持有”。HC Wainwright 在周三的研究报告中将 Arcus Biosciences 的目标价从 24.00 美元上调至 28.00 美元，并给予该股 “买入” 评级。富国银行在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该股 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Arcus Biosciences 的 “卖出（d-）” 评级。七位研究分析师对该股给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股目前的共识评级为 “适度买入”，共识目标价为 27.67 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
<p><strong>查看我们关于 Arcus Biosciences 的最新股票报告</strong></p>
<h2>Arcus Biosciences 的内部买卖</h2>
<p>在其他 Arcus Biosciences 的新闻中，首席财务官 Robert C. Goeltz II 于 10 月 28 日出售了 5,000 股 Arcus Biosciences 股票。股票以平均价格 20.00 美元出售，总交易额为 100,000.00 美元。交易后，首席财务官直接持有该公司 92,138 股股票，价值 1,842,760 美元。此次交易使其持股减少了 5.15%。该出售在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，首席运营官 Jennifer Jarrett 于 10 月 8 日出售了 37,792 股该公司的股票。股票以平均价格 15.05 美元出售，总交易额为 568,769.60 美元。交易后，首席运营官直接持有该公司 214,232 股股票，价值约 3,224,191.60 美元。此次交易使其持股减少了 15.00%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了价值 906,081 美元的 59,702 股公司股票。公司内部人士持有该公司 9.60% 的股份。</p>
<h2>对 Arcus Biosciences 的对冲基金看法</h2>
<ul>
<li>吉利德通过在 AlloVir 和 Arcus 中增持生物科技足迹</li>
</ul>
<p>几位大型投资者最近对该公司的持仓进行了调整。Amalgamated Bank 在第三季度将其在 Arcus Biosciences 的持仓增加了 3.9%。Amalgamated Bank 目前持有该公司 19,533 股股票，价值 266,000 美元，此前在上个季度又购买了 736 股。Nordea Investment Management AB 在第三季度将其在 Arcus Biosciences 的持仓增加了 2.7%。Nordea Investment Management AB 目前持有该公司 328,459 股股票，价值 4,332,000 美元，此前在上个季度又购买了 8,560 股。SG Americas Securities LLC 在第三季度将其在 Arcus Biosciences 的持仓增加了 19.8%。SG Americas Securities LLC 目前持有该公司 32,774 股股票，价值 446,000 美元，此前在上个季度又购买了 5,412 股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持仓增加了 59.1%。GAMMA Investing LLC 目前持有该公司 2,748 股股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。最后，Corient Private Wealth LLC 在第二季度购买了 Arcus Biosciences 的新股份，价值约 180,000 美元。机构投资者持有该公司 92.89% 的股份。</p>
<h2>Arcus Biosciences 股价上涨 9.0%</h2>
<p>该公司的速动比率为 4.50，流动比率为 4.50，债务与股本比率为 0.18。该公司的市值为 23.1 亿美元，市盈率为 -6.83，贝塔值为 0.77。该公司的 50 日简单移动平均线为 13.37 美元，200 日简单移动平均线为 10.50 美元。</p>
<h2>关于 Arcus Biosciences</h2>
<p>（获取免费报告）</p>
<p>Arcus Biosciences, Inc. 是一家临床阶段的生物制药公司，在美国开发和商业化癌症疗法。该公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于 2 期和 3 期临床试验；以及 AB308，一种研究性抗 TIGIT 单克隆抗体，目前正在进行 1b 期临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Arcus Biosciences 更好的股票</li>
<li>通过这些股息之王度过衰退</li>
<li>忘掉人工智能：亚马逊的机器人可能会抢走你的工作</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>Wayfair：一只值得在 2026 年买入并持有的好股票</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>福特的指引下调未能阻止新 52 周高点</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
<p>在你考虑 Arcus Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arcus Biosciences 并不在名单上。</p>
<p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>Arcus Biosciences（纽约证券交易所代码：RCUS）的股价上涨了 9%，交易价格为 21.66 美元。该公司报告的每股收益为（1.27 美元），超过了（1.33 美元）的预期，收入为 2600 万美元，超出了 1989 万美元的预测。分析师设定的共识目标价为 27.67 美元，其中七位分析师给予 “买入” 评级。内部人士的卖出情况被注意到，首席财务官 Robert C. Goeltz II 出售了 5000 股。机构投资者持有该股票的 92.89%，反映出对公司的强烈兴趣</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price traded up 9% during mid-day trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $21.46 and last traded at $21.6620. 878,698 shares were traded during mid-day trading, a decline of 15% from the average session volume of 1,028,993 shares. The stock had previously closed at $19.88.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股价在周三的午盘交易中上涨了 9%，原因是其财报超出预期。该股最高交易价为 21.46 美元，最后交易价为 21.6620 美元。午盘交易中成交了 878,698 股，较平均交易量 1,028,993 股下降了 15%。该股此前收盘价为 19.88 美元。</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从滞后者到领头羊：小型股正在崛起</li>
</ul>
</div><p>The company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The business had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same quarter last year, the company posted ($1.00) EPS. Arcus Biosciences's revenue for the quarter was down 45.8% on a year-over-year basis.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为（1.27 美元），超出分析师一致预期的（1.33 美元）0.06 美元。Arcus Biosciences 的股本回报率为负 55.96%，净利润率为负 109.56%。该季度的收入为 2600 万美元，而分析师预期为 1989 万美元。去年同期，该公司的每股收益为（1.00 美元）。Arcus Biosciences 本季度的收入同比下降了 45.8%。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts recently commented on the company. Truist Financial reaffirmed a &#34;buy&#34; rating and issued a $39.00 price target (up previously from $32.00) on shares of Arcus Biosciences in a research note on Tuesday, October 7th. Wall Street Zen upgraded Arcus Biosciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 9th. HC Wainwright boosted their target price on Arcus Biosciences from $24.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday. Wells Fargo &amp; Company boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, October 20th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $27.67.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。Truist Financial 在 10 月 7 日的研究报告中重申了 “买入” 评级，并将 Arcus Biosciences 的目标价从 32.00 美元上调至 39.00 美元。华尔街 Zen 在 8 月 9 日的研究报告中将 Arcus Biosciences 的评级从 “强烈卖出” 上调至 “持有”。HC Wainwright 在周三的研究报告中将 Arcus Biosciences 的目标价从 24.00 美元上调至 28.00 美元，并给予该股 “买入” 评级。富国银行在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该股 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Arcus Biosciences 的 “卖出（d-）” 评级。七位研究分析师对该股给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股目前的共识评级为 “适度买入”，共识目标价为 27.67 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Arcus Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Arcus Biosciences 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling at Arcus Biosciences</h2>
<div class="lb-trans"><h2>Arcus Biosciences 的内部买卖</h2>
</div><p>In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 5,000 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the chief financial officer directly owned 92,138 shares of the company's stock, valued at $1,842,760. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Jennifer Jarrett sold 37,792 shares of the business's stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $15.05, for a total transaction of $568,769.60. Following the transaction, the chief operating officer directly owned 214,232 shares in the company, valued at approximately $3,224,191.60. The trade was a 15.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,702 shares of company stock valued at $906,081 over the last ninety days. Corporate insiders own 9.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Arcus Biosciences 的新闻中，首席财务官 Robert C. Goeltz II 于 10 月 28 日出售了 5,000 股 Arcus Biosciences 股票。股票以平均价格 20.00 美元出售，总交易额为 100,000.00 美元。交易后，首席财务官直接持有该公司 92,138 股股票，价值 1,842,760 美元。此次交易使其持股减少了 5.15%。该出售在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，首席运营官 Jennifer Jarrett 于 10 月 8 日出售了 37,792 股该公司的股票。股票以平均价格 15.05 美元出售，总交易额为 568,769.60 美元。交易后，首席运营官直接持有该公司 214,232 股股票，价值约 3,224,191.60 美元。此次交易使其持股减少了 15.00%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了价值 906,081 美元的 59,702 股公司股票。公司内部人士持有该公司 9.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Arcus Biosciences</h2>
<div class="lb-trans"><h2>对 Arcus Biosciences 的对冲基金看法</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通过在 AlloVir 和 Arcus 中增持生物科技足迹</li>
</ul>
</div><p>Several large investors have recently made changes to their positions in the business. Amalgamated Bank boosted its position in shares of Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company's stock valued at $266,000 after purchasing an additional 736 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Arcus Biosciences by 2.7% during the 3rd quarter. Nordea Investment Management AB now owns 328,459 shares of the company's stock valued at $4,332,000 after purchasing an additional 8,560 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Arcus Biosciences by 19.8% during the 3rd quarter. SG Americas Securities LLC now owns 32,774 shares of the company's stock valued at $446,000 after purchasing an additional 5,412 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in Arcus Biosciences during the second quarter valued at about $180,000. Institutional investors own 92.89% of the company's stock.</p>
<div class="lb-trans"><p>几位大型投资者最近对该公司的持仓进行了调整。Amalgamated Bank 在第三季度将其在 Arcus Biosciences 的持仓增加了 3.9%。Amalgamated Bank 目前持有该公司 19,533 股股票，价值 266,000 美元，此前在上个季度又购买了 736 股。Nordea Investment Management AB 在第三季度将其在 Arcus Biosciences 的持仓增加了 2.7%。Nordea Investment Management AB 目前持有该公司 328,459 股股票，价值 4,332,000 美元，此前在上个季度又购买了 8,560 股。SG Americas Securities LLC 在第三季度将其在 Arcus Biosciences 的持仓增加了 19.8%。SG Americas Securities LLC 目前持有该公司 32,774 股股票，价值 446,000 美元，此前在上个季度又购买了 5,412 股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持仓增加了 59.1%。GAMMA Investing LLC 目前持有该公司 2,748 股股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。最后，Corient Private Wealth LLC 在第二季度购买了 Arcus Biosciences 的新股份，价值约 180,000 美元。机构投资者持有该公司 92.89% 的股份。</p>
</div><h2>Arcus Biosciences Stock Up 9.0%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股价上涨 9.0%</h2>
</div><p>The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.31 billion, a PE ratio of -6.83 and a beta of 0.77. The business's 50 day simple moving average is $13.37 and its 200 day simple moving average is $10.50.</p>
<div class="lb-trans"><p>该公司的速动比率为 4.50，流动比率为 4.50，债务与股本比率为 0.18。该公司的市值为 23.1 亿美元，市盈率为 -6.83，贝塔值为 0.77。该公司的 50 日简单移动平均线为 13.37 美元，200 日简单移动平均线为 10.50 美元。</p>
</div><h2>About Arcus Biosciences</h2>
<div class="lb-trans"><h2>关于 Arcus Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc. 是一家临床阶段的生物制药公司，在美国开发和商业化癌症疗法。该公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于 2 期和 3 期临床试验；以及 AB308，一种研究性抗 TIGIT 单克隆抗体，目前正在进行 1b 期临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>Forget AI: Amazon's Robots Could Be Coming for Your Job</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>Wayfair: A Way Good Stock to Buy and Hold for 2026</li>
<li>Insider Trading - What You Need to Know</li>
<li>Ford's Guidance Cut Couldn't Stop a New 52-Week High</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Arcus Biosciences 更好的股票</li>
<li>通过这些股息之王度过衰退</li>
<li>忘掉人工智能：亚马逊的机器人可能会抢走你的工作</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>Wayfair：一只值得在 2026 年买入并持有的好股票</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>福特的指引下调未能阻止新 52 周高点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Arcus Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcus Biosciences（NYSE:RCUS）因盈利好于预期而股价上涨 9%